Delaney, John M.,Fanslow, William Christian,King, Chadwick Terence
申请号：
NZ71782012
公开号：
NZ717820A
申请日:
2012.09.20
申请国别(地区):
NZ
年份:
2020
代理人:
摘要：
Disclosed are CD27L antigen binding proteins. In an embodiment the CD27L antigen binding protein has: a) a light chain variable domain comprising an LCDR1 having no more than three amino acid additions, deletions, or substitutions from the LCDR1 sequence set forth in SEQ ID NO:71； an LCDR2 having no more than two amino acid additions, deletions, or substitutions from the LCDR2 sequence set forth in SEQ ID NO:79； and an LCDR3 having no more than two amino acid additions, deletions, or substitutions from the LCDR3 sequence set forth in SEQ ID NO:87； and a heavy chain variable domain comprising an HCDR1 having no more than one amino acid addition, deletion, or substitution from the HCDR1 sequence set forth in SEQ ID NO:25； an HCDR2 having no more than three amino acid additions, deletions, or substitutions from the HCDR2 sequence set forth in SEQ ID NO:33； and an HCDR3 having no more than three amino acid additions, deletions, or substitutions from the HCDR3 sequence set forth in SEQ ID NO:41； or b) an LCDR1 having no more than three amino acid additions, deletions, or substitutions from the LCDR1 sequence set forth in SEQ ID NO:72； an LCDR2 having no more than two amino acid additions, deletions, or substitutions from the LCDR2 sequence set forth in SEQ ID NO:80； and an LCDR3 having no more than two amino acid additions, deletions, or substitutions from the LCDR3 sequence set forth in SEQ ID NO:88； and a heavy chain variable domain comprising an HCDR1 having no more than one amino acid addition, deletion, or substitution from the HCDR1 sequence set forth in SEQ ID NO:26； an HCDR2 having no more than three amino acid additions, deletions, or substitutions from the HCDR2 sequence set forth in SEQ ID NO:34； and an HCDR3 having no more than three amino acid additions, deletions, or substitutions from the HCDR3 sequence set forth in SEQ ID NO:42.
